65,437 trials
Migraine Headache
Primary: Mean Change From Baseline in the Number of Migraine Headache Days in the Last 28-Day Period of the 12-Week Treatment Phase — -3.66; -4.23; -3.92; -4.80 Days
Rhabdomyosarcoma · Malignant Peripheral Nerve Sheath Tumors · Chondrosarcoma
Primary: Response Rate: Number of Participants With Objective Tumor Response — 12; 14; 20 Participants
Appendicitis
Primary: Post-operative Wound Infection, After Open Appendectomy — 1; 7 Participants
Solitary Pulmonary Nodule · Biopsy, Fine-Needle
Primary: Acquisition of Adequate Specimens of Targeted Lung Lesions — 9 Participants
Peripheral T-Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) and Recommended Dose (RD) — 9 ug/kg/day
Asthma · Healthy Subjects or Volunteers
Primary: Area Under the Concentration-Time Curve From Zero to Infinity (AUC [0-infinity]) — 1426.47; 1243.28; 1251.63; 897.02 day*mcg/mL
Severe Hemophilia B
Primary: Number of Participants With Any Positive Inhibitor Development — 0; 0; 0 Participants
Gastroenteritis
Primary: Number of Participants With Solicited Local Adverse Events (AEs) Post Dose 1 — 4; 5; 6; 5 participants
Asthma
Primary: Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at Week 4 — 0.065; 0.017 Liters — p=0.282
Breast Cancer
Primary: Patients With Reduction in Incidental Radiation — 46 Participants
Portopulmonary Hypertension
Primary: Relative Change From Baseline to Week 12 in Pulmonary Vascular Resistance (PVR). — 0.63; 0.98 ratio — p=0.0001
Homosexuality · Gender Identity
Primary: Communication Climate Assessment Toolkit Questionnaire (Patient) — 92.78; 91.32; 94.14 Score
Parkinson Disease · Multiple System Atrophy
Primary: Change in Verbal Fluency FAS (F, A or S Words) Total Score — 38.8; 41.0; 32.8; 30.8 Words
Solid Tumor · Kidney Cancer
Primary: Maximum Tolerated Dose (MTD) [Phase I Dose Finding] — 400 mg
Urinary Incontinence
Primary: Total Incontinence Frequency — -2.8; -1.9 episodes per day — p=0.13